Linezolid 600Mg Tab

DRUG2 trials

Sponsors

Médecins Sans Frontières, France, TASK Applied Science

Conditions

Bacterial InfectionsGram-Positive Bacterial InfectionsMycobacterial InfectionsPulmonary TuberculosesTuberculosisTuberculosis, Multidrug-ResistantTuberculosis, Pulmonary

Phase 2

Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

Not yet recruitingNCT07773610

TASK Applied ScienceTuberculosis, Pulmonary

Start: 2026-07-23End: 2027-12-30Target: 135Updated: 2026-08-19

Phase 3

Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

CompletedNCT03896685

Médecins Sans Frontières, FranceTuberculosis, Multidrug-Resistant, Tuberculosis, Pulmonary Tuberculoses +3

Start: 2020-04-06End: 2024-12-31Updated: 2025-02-10

Related Papers

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

2025-07-166 citations

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.

2023-11-3012 citations

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.

2021-09-2522 citations